Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs Victoria's Secret & Co (VSXY) Price & Performance

BioNano Genomics IncTrade
Victoria's Secret & CoTrade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs Victoria's Secret & Co — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Victoria's Secret & Co trades at $83.12 (market cap $6.51B). The key difference: Victoria's Secret & Co is far larger — about 493.2× BioNano Genomics Inc's market cap, and Victoria's Secret & Co is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.

BNGOVSXY
Market Cap
$13.20M$6.51B
Sector
HealthConsumer Cyclical
52-Week High
$4.92$88.50
52-Week Low
$1.09$17.70
Enterprise Value
$15.81M$9.16B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.

BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.

Victoria's Secret & Co

Victoria's Secret (VSXY) trades at $78.98, up 0.79% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats and international growth momentum, particularly a 44.9% surge in Q1 2026 international sales, highlight operational improvements. The stock shows recovering profitability with a net income margin of 3.12% and robust ROE of 29.41%, though valuation metrics like a P/E of 31.47 suggest premium pricing relative to earnings.

The outlook remains positive with a consensus price target of $88.56 implying 12% upside, driven by innovation and global expansion. Risks include competitive pressures and reliance on margin recovery. Institutional sentiment is favorable with no sell ratings, but investors should monitor execution on growth initiatives and macroeconomic impacts on consumer spending.

Returns comparison

Trailing returns across standard periods

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About Victoria's Secret & Co

Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.

Read more on VSXY